Madurella mycetomatis is highly susceptible to ravuconazole.
The current treatment of eumycetoma utilizing ketoconazole is unsatisfactory because of high recurrence rates, which often leads to complications and unnecessary amputations, and its comparatively high cost in endemic areas. Hence, an effective and affordable drug is required to improve therapeutic...
Published in: | PLoS Neglected Tropical Diseases |
---|---|
Main Authors: | , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014
|
Subjects: | |
Online Access: | https://doi.org/10.1371/journal.pntd.0002942 https://doaj.org/article/b4260b40284b469d8c6a853b79b085f2 |
id |
ftdoajarticles:oai:doaj.org/article:b4260b40284b469d8c6a853b79b085f2 |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:b4260b40284b469d8c6a853b79b085f2 2023-05-15T15:05:37+02:00 Madurella mycetomatis is highly susceptible to ravuconazole. Sarah Abdalla Ahmed Wendy Kloezen Frederick Duncanson Ed E Zijlstra G Sybren de Hoog Ahmed H Fahal Wendy W J van de Sande 2014-06-01T00:00:00Z https://doi.org/10.1371/journal.pntd.0002942 https://doaj.org/article/b4260b40284b469d8c6a853b79b085f2 EN eng Public Library of Science (PLoS) http://europepmc.org/articles/PMC4063742?pdf=render https://doaj.org/toc/1935-2727 https://doaj.org/toc/1935-2735 1935-2727 1935-2735 doi:10.1371/journal.pntd.0002942 https://doaj.org/article/b4260b40284b469d8c6a853b79b085f2 PLoS Neglected Tropical Diseases, Vol 8, Iss 6, p e2942 (2014) Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 article 2014 ftdoajarticles https://doi.org/10.1371/journal.pntd.0002942 2022-12-31T11:51:04Z The current treatment of eumycetoma utilizing ketoconazole is unsatisfactory because of high recurrence rates, which often leads to complications and unnecessary amputations, and its comparatively high cost in endemic areas. Hence, an effective and affordable drug is required to improve therapeutic outcome. E1224 is a potent orally available, broad-spectrum triazole currently being developed for the treatment of Chagas disease. E1224 is a prodrug that is rapidly converted to ravuconazole. Plasma levels of E1224 are low and transient, and its therapeutically active moiety, ravuconazole is therapeutically active. In the present study, the in vitro activity of ravuconazole against Madurella mycetomatis, the most common etiologic agent of eumycetoma, was evaluated and compared to that of ketoconazole and itraconazole. Ravuconazole showed excellent activity with MICs ranging between ≤ 0.002 and 0.031 µg/ml, which were significantly lower than the MICs reported for ketoconazole and itraconazole. On the basis of our findings, E1224 with its resultant active moiety, ravuconazole, could be an effective and affordable therapeutic option for the treatment of eumycetoma. Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic PLoS Neglected Tropical Diseases 8 6 e2942 |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
English |
topic |
Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 |
spellingShingle |
Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 Sarah Abdalla Ahmed Wendy Kloezen Frederick Duncanson Ed E Zijlstra G Sybren de Hoog Ahmed H Fahal Wendy W J van de Sande Madurella mycetomatis is highly susceptible to ravuconazole. |
topic_facet |
Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 |
description |
The current treatment of eumycetoma utilizing ketoconazole is unsatisfactory because of high recurrence rates, which often leads to complications and unnecessary amputations, and its comparatively high cost in endemic areas. Hence, an effective and affordable drug is required to improve therapeutic outcome. E1224 is a potent orally available, broad-spectrum triazole currently being developed for the treatment of Chagas disease. E1224 is a prodrug that is rapidly converted to ravuconazole. Plasma levels of E1224 are low and transient, and its therapeutically active moiety, ravuconazole is therapeutically active. In the present study, the in vitro activity of ravuconazole against Madurella mycetomatis, the most common etiologic agent of eumycetoma, was evaluated and compared to that of ketoconazole and itraconazole. Ravuconazole showed excellent activity with MICs ranging between ≤ 0.002 and 0.031 µg/ml, which were significantly lower than the MICs reported for ketoconazole and itraconazole. On the basis of our findings, E1224 with its resultant active moiety, ravuconazole, could be an effective and affordable therapeutic option for the treatment of eumycetoma. |
format |
Article in Journal/Newspaper |
author |
Sarah Abdalla Ahmed Wendy Kloezen Frederick Duncanson Ed E Zijlstra G Sybren de Hoog Ahmed H Fahal Wendy W J van de Sande |
author_facet |
Sarah Abdalla Ahmed Wendy Kloezen Frederick Duncanson Ed E Zijlstra G Sybren de Hoog Ahmed H Fahal Wendy W J van de Sande |
author_sort |
Sarah Abdalla Ahmed |
title |
Madurella mycetomatis is highly susceptible to ravuconazole. |
title_short |
Madurella mycetomatis is highly susceptible to ravuconazole. |
title_full |
Madurella mycetomatis is highly susceptible to ravuconazole. |
title_fullStr |
Madurella mycetomatis is highly susceptible to ravuconazole. |
title_full_unstemmed |
Madurella mycetomatis is highly susceptible to ravuconazole. |
title_sort |
madurella mycetomatis is highly susceptible to ravuconazole. |
publisher |
Public Library of Science (PLoS) |
publishDate |
2014 |
url |
https://doi.org/10.1371/journal.pntd.0002942 https://doaj.org/article/b4260b40284b469d8c6a853b79b085f2 |
geographic |
Arctic |
geographic_facet |
Arctic |
genre |
Arctic |
genre_facet |
Arctic |
op_source |
PLoS Neglected Tropical Diseases, Vol 8, Iss 6, p e2942 (2014) |
op_relation |
http://europepmc.org/articles/PMC4063742?pdf=render https://doaj.org/toc/1935-2727 https://doaj.org/toc/1935-2735 1935-2727 1935-2735 doi:10.1371/journal.pntd.0002942 https://doaj.org/article/b4260b40284b469d8c6a853b79b085f2 |
op_doi |
https://doi.org/10.1371/journal.pntd.0002942 |
container_title |
PLoS Neglected Tropical Diseases |
container_volume |
8 |
container_issue |
6 |
container_start_page |
e2942 |
_version_ |
1766337282806120448 |